From today, the Australian government will expand Pharmaceutical Benefits Scheme (PBS) access to the drug Keytruda for three ...
Keytruda did not significantly impact long-term health-related quality of life in stage 3 melanoma patients compared to placebo. Both Keytruda and placebo groups returned to baseline quality of life ...
Trodelvy plus Keytruda improved progression-free survival in PD-L1–positive, advanced TNBC, reducing disease progression or death risk by 35% compared to chemotherapy plus Keytruda. The phase 3 ASCENT ...
What Is It, and Why Does It Matter? The FDA has approved a new combination therapy for adults with epithelial cancers that start in the ovaries, fallopian tubes, or lining of the abdomen (peritoneum).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results